SNTI
Senti Biosciences Holdings, Inc.Company Information
- Company Name
- Senti Biosciences Holdings, Inc.
- CIK
- CIK0001854270
- Category
- <br>Emerging growth company
- Ticker: Exchange
- SNTI: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- SNTI
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2025-02-06
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 727
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 4,873,598
- Shares outstanding
- 31,144,754
- Ownership
- 15.65%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -25.84%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nonrelated Party | -0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | ||||||
| Related Party | -0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | -19 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 6 | 9 | 16 | 12 | 22 | 34 | 48 | 10 | 16 | 24 | 36 | 39 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Assets Current | 13 | 15 | 23 | 18 | 33 | 45 | 59 | 17 | 44 | 56 | 71 | 79 | ||||||
| Accounts Receivable Net Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Restricted Cash | 1 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 6 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Property Plant And Equipment Net | 11 | 12 | 13 | 19 | 20 | 21 | 21 | 22 | 23 | 24 | 25 | 26 | ||||||
| Operating Lease Right Of Use Asset | 7 | 8 | 12 | 12 | 13 | 13 | 14 | 14 | 15 | 16 | 16 | 17 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 33 | 38 | 51 | 53 | 69 | 83 | 98 | 58 | 87 | 102 | 119 | 132 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | ||||||
| Disposal Group Including Discontinued Operation Assets Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Finance Lease Liability Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 4 | 5 | 5 | 5 | 4 | 4 | 6 | 3 | 3 | 3 | 6 | 4 | ||||||
| Convertible Debt Current | 4 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 3 | 6 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 3 | ||||||
| Business Combination Contingent Consideration Liability Current | - | - | - | - | - | - | - | 0 | 0 | - | - | - | ||||||
| Contract With Customer Liability Current | 0 | 0 | 0 | - | - | - | 0 | - | - | - | 0 | 0 | ||||||
| Liabilities Current | 16 | 14 | 14 | 12 | 10 | 11 | 13 | 9 | 9 | 10 | 13 | 10 | ||||||
| Finance Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Operating Lease Liability Noncurrent | 13 | 13 | 24 | 25 | 26 | 28 | 29 | 30 | 31 | 32 | 34 | 35 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Liabilities Noncurrent | 8 | 8 | 8 | 8 | 8 | 7 | 5 | 3 | - | - | 0 | - | ||||||
| Liabilities | 37 | 36 | 46 | 45 | 44 | 45 | 47 | 42 | 43 | 46 | 53 | 49 | ||||||
| Preferred Stock Value | - | - | - | - | - | - | - | 0 | 0 | 0 | - | 0 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Derivative Liabilities Noncurrent | - | - | - | - | - | - | 0 | 0 | 2 | 4 | 6 | 4 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | 0 | 0 | 0 | 0 | 0 | 25 | 0 | 0 | 0 | 0 | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 372 | 365 | 364 | 352 | 351 | 349 | 323 | 313 | 312 | 313 | 311 | 309 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -376 | -363 | -359 | -344 | -326 | -311 | -297 | -297 | -268 | -256 | -244 | -226 | ||||||
| Stockholders Equity | -3 | 3 | 6 | 8 | 25 | 38 | 26 | 16 | 44 | 56 | 67 | 83 | ||||||
| Liabilities And Stockholders Equity | 33 | 38 | 51 | 53 | 69 | 83 | 98 | 58 | 87 | 102 | 119 | 132 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | - | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | - | - | 10 | 10 | 10 | - | 10 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | 0 | 0 | 0 | - | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | 0 | 0 | 0 | - | 0 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Temporary Equity Shares Authorized | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Temporary Equity Shares Issued | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Common Stock Shares Issued | 31 | 31 | 31 | 26 | 26 | 26 | 5 | 5 | 5 | 5 | 5 | 4 | ||||||
| Shares Outstanding | 31 | 31 | 31 | 26 | 26 | 26 | 5 | 5 | 5 | 5 | 5 | 4 | ||||||
| Temporary Equity Shares Outstanding | - | 0 | 0 | 0 | 0 | 0 | 21 | 0 | 0 | 0 | 0 | - | ||||||
| Temporary Equity Liquidation Preference | - | - | 0 | 0 | 0 | 0 | 148 | - | - | - | 0 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSenti Biosciences Holdings, Inc. (SNTI) — SEC Financial Statements & Analysis
Senti Biosciences Holdings, Inc. (SNTI) is a biological products, (no diagnostic substances) company, incorporated in DE. Senti Biosciences Holdings, Inc. trades on Nasdaq as: SNTI. Senti Biosciences Holdings, Inc. (SNTI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Senti Biosciences Holdings, Inc. carries a market cap of $34.26M, a P/E ratio of -0.69x, a P/B ratio of -10.07x, a P/S ratio of 1038.16x, an enterprise value of $30.36M, and an EV/EBITDA multiple of -0.59x. On profitability, it posts an operating margin of -165724.24%, a net margin of -150193.94%, a Return on Equity (ROE) of -466.46%, a Return on Assets (ROA) of -97.52%, and a Return on Invested Capital (ROIC) of -370.41%. Per share, it reports EPS of $-1.59, diluted EPS of $-1.59, free cash flow per share of $-1.22, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -15.02% year-over-year, and EPS growth of -28.83% year-over-year. On the balance sheet, it maintains a current ratio of 0.83x, a quick ratio of 0.83x, working capital of $-2.76M, a debt-to-equity ratio of -10.73x, a debt ratio of 1.1, an interest coverage ratio of -130.52x, free cash flow of $-38.05M (TTM), and net debt of $-3.90M. Figures sourced from SEC EDGAR.
- Market Cap
- $34.26M
- P/E TTM
- -0.69x
- EPS TTM
- $-1.59
- P/B TTM
- -10.07x
- ROE TTM
- -466.46%
- ROA TTM
- -97.52%
- Debt To Equity
- -10.73x
- Free Cash Flow TTM
- $-38.05M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Senti Biosciences Holdings, Inc. in?
Senti Biosciences Holdings, Inc. (SNTI) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does SNTI trade on?
Senti Biosciences Holdings, Inc. (SNTI) trades on the Nasdaq.
Where is Senti Biosciences Holdings, Inc. incorporated?
Senti Biosciences Holdings, Inc. is incorporated in DE.
When was Senti Biosciences Holdings, Inc. (SNTI)'s most recent SEC filing?
Senti Biosciences Holdings, Inc. (SNTI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is SNTI's market cap?
Senti Biosciences Holdings, Inc. (SNTI) has a market capitalization of $34.26M as of 2026-06-30.
What is SNTI's EPS (earnings per share)?
Senti Biosciences Holdings, Inc. (SNTI)'s trailing twelve month EPS is $-1.59 as of 2026-06-30.
What is SNTI's ROE (return on equity)?
Senti Biosciences Holdings, Inc. (SNTI)'s trailing twelve month Return on Equity (ROE) is -466.46% as of 2026-06-30.
What is SNTI's ROA (return on assets)?
Senti Biosciences Holdings, Inc. (SNTI)'s trailing twelve month Return on Assets (ROA) is -97.52% as of 2026-06-30.
What is SNTI's ROIC (return on invested capital)?
Senti Biosciences Holdings, Inc. (SNTI)'s trailing twelve month Return on Invested Capital (ROIC) is -370.41% as of 2025-03-31.
What is SNTI's EV/EBITDA?
Senti Biosciences Holdings, Inc. (SNTI)'s trailing twelve month EV/EBITDA is -0.59x as of 2026-06-30.